These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35303014)

  • 41. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial.
    Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J; Sun Y
    Int J Cancer; 2019 Jul; 145(1):295-305. PubMed ID: 30613964
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study.
    Liu L; Fei Z; Chen M; Zhao L; Su H; Gu D; Lin B; Cai X; Lu L; Gao M; Ye X; Jin X; Xie C
    Radiat Oncol; 2018 Aug; 13(1):148. PubMed ID: 30103765
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
    Lin M; You R; Liu YP; Zhang YN; Zhang HJ; Zou X; Yang Q; Li CF; Hua YJ; Yu T; Cao JY; Li JB; Mo HY; Guo L; Lin AH; Sun Y; Qian CN; Ma J; Mai HQ; Chen MY
    Oral Oncol; 2018 May; 80():1-8. PubMed ID: 29706183
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis.
    Tan TH; Soon YY; Cheo T; Ho F; Wong LC; Tey J; Tham IWK
    Radiother Oncol; 2018 Oct; 129(1):10-17. PubMed ID: 29555182
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.
    Huang PY; Zeng Q; Cao KJ; Guo X; Guo L; Mo HY; Wu PH; Qian CN; Mai HQ; Hong MH
    Eur J Cancer; 2015 Sep; 51(13):1760-70. PubMed ID: 26093812
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas.
    Petit C; Blanchard P; Pignon JP; Lueza B
    Syst Rev; 2019 Apr; 8(1):96. PubMed ID: 30987679
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The addition of nimotuzumab during concurrent chemoradiotherapy improved survival outcomes in locally advanced nasopharyngeal carcinoma patients with optimal response to induction chemotherapy.
    Guo LF; Rao MY; Yu YF; Lin Q; Wu SG
    BMC Cancer; 2024 Aug; 24(1):950. PubMed ID: 39095737
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The evaluation of adding induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: a meta-analysis.
    Tang M; Jia Z; Zhang J
    Eur Arch Otorhinolaryngol; 2021 May; 278(5):1545-1558. PubMed ID: 32700235
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
    Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
    Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Locoregional Control and Mild Late Toxicity After Reducing Target Volumes and Radiation Doses in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy (IC) Followed by Concurrent Chemoradiotherapy: 10-Year Results of a Phase 2 Study.
    Zhao C; Miao JJ; Hua YJ; Wang L; Han F; Lu LX; Xiao WW; Wu HJ; Zhu MY; Huang SM; Lin CG; Deng XW; Xie CH
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):836-844. PubMed ID: 30954521
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
    Setakornnukul J; Thephamongkhol K
    BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Huang PY; Cao KJ; Guo X; Mo HY; Guo L; Xiang YQ; Deng MQ; Qiu F; Cao SM; Guo Y; Zhang L; Li NW; Sun R; Chen QY; Luo DH; Hua YJ; Mai HQ; Hong MH
    Oral Oncol; 2012 Oct; 48(10):1038-1044. PubMed ID: 22591726
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial.
    Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J
    Eur J Cancer; 2017 Apr; 75():150-158. PubMed ID: 28235726
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of the Additional Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy for Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: a Bayesian Network Meta-analysis of Randomized Controlled Trials.
    Chen YP; Guo R; Liu N; Liu X; Mao YP; Tang LL; Zhou GQ; Lin AH; Sun Y; Ma J
    J Cancer; 2015; 6(9):883-92. PubMed ID: 26284140
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
    Dai J; Zhang B; Su Y; Pan Y; Ye Z; Cai R; Qin G; Kong X; Mo Y; Zhang R; Liu Z; Xie Y; Ruan X; Jiang W
    JAMA Oncol; 2024 Apr; 10(4):456-463. PubMed ID: 38329737
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of Chemoradiotherapy Regimens and Survival Among Patients With Nasopharyngeal Carcinoma: A Systematic Review and Meta-analysis.
    Zhang B; Li MM; Chen WH; Zhao JF; Chen WQ; Dong YH; Gong X; Chen QY; Zhang L; Mo XK; Luo XN; Tian J; Zhang SX
    JAMA Netw Open; 2019 Oct; 2(10):e1913619. PubMed ID: 31626318
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Positive effect of high RKIP expression on reduced distant metastasis by chemotherapy when combined with radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a prospective study.
    Li SW; Wang H; Liu ML; Zhang HB; Xiang YQ; Lv X; Xia WX; Zeng MS; Mai HQ; Hong MH; Guo X
    Med Oncol; 2013 Mar; 30(1):322. PubMed ID: 23254962
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma.
    Wang Q; Xu G; Xia Y; Zuo J; Zeng G; Xue Z; Cao R; Xiong W; Li W
    Oral Oncol; 2020 Dec; 111():104925. PubMed ID: 32721816
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Two-year outcome of concurrent chemoradiation with carboplatin with or without adjuvant carboplatin/fluorouracil in nasopharyngeal cancer: A multicenter randomized trial.
    Chitapanarux I; Kittichest R; Tungkasamit T; Asakit T; Chomprasert K; Chakrabandhu S; Onchan W; Traisathit P
    Curr Probl Cancer; 2021 Feb; 45(1):100620. PubMed ID: 32713518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.